Drug Profile
Research programme: cancer therapeutics - Entomed
Latest Information Update: 21 Mar 2007
Price :
$50
*
At a glance
- Originator Entomed
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Nov 2002 Entomed is seeking corporate alliances for its anticancer programme (http://www.entomed.com)
- 18 Nov 2002 Preclinical trials in Cancer in France (unspecified route)